News Chart Monte Rosa Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX 16:43:19 02/09/2026 +03			5-day change	1st Jan Change
14.72 ^USD	+2.83%		-1.72%	-8.74%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

1236d909d71a8.DFP6HyqlqXkX-qomdK6rE3wXwuC5aNDMBzKiJC79rio.VT-cbF_L4wBTvfxlRfvdcRt8jprfG524dH_abxuF4GF2MrxPTM3jEFCIwQ~308914a47fc4d081fa542b3cdafbc3eb